Certolizumab pegol - Psoriasis

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549

The Surrey & North West Sussex Area Prescribing Committee (APC) recommends certolizumab pegol as a treatment option in adult patients with moderate to severe plaque psoriasis in line with NICE TA 574 (April 2019)

Certolizumab pegol is a payment by results excluded medicine and initiation and subsequent monitoring of response will be by the dermatology specialist service. Blueteq forms for initiation and continuation will be available for completion by specialist teams.

Certolizumab pegol will be considered as RED on the traffic light system

Dose escalation to 400mg every 2 weeks is supported by APC whilst the manufacturer has the same Patient Access Scheme (PAS) in place noted by APC in June 2019.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.